FDA Calls Vets and Drug Makers to Animal Fee Renewal Talks
Published Date: 5/11/2026
Notice
Summary
The FDA is inviting vets, animal drug makers, and animal lovers to join meetings about renewing the Animal Drug User Fee Act before it expires in 2028. These meetings, starting June 2026 and happening every four months, will help decide how fees for animal drug reviews are set and used. If you want to have a say, let the FDA know by June 1, 2026!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
ADUFA Authority Ends September 30, 2028
The current Animal Drug User Fee Act authority (ADUFA V) expires September 30, 2028. The notice states that without new legislation to reauthorize the program, FDA will no longer be able to collect user fees for future fiscal years to fund the new animal drug review process.
Stakeholder Sign‑up Deadline: June 1, 2026
If you represent a stakeholder group (veterinary professionals, patient and consumer advocacy groups, or scientific and academic experts) and want to join FDA’s ADUFA reauthorization discussions, notify FDA by email at [email protected] by June 1, 2026. Stakeholders who notify will be included in future stakeholder discussions while FDA negotiates with the regulated industry.
Scheduled Consultation Meetings Starting June 2026
FDA will hold stakeholder consultation meetings beginning in June 2026 and will continue meeting at least once every 4 months during ADUFA reauthorization negotiations. Meetings will be held in person at the FDA Harvey W. Wiley Federal Building, 5001 Campus Drive, College Park, MD 20740, and virtually via Microsoft Teams.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
Previous / Next Documents
Previous: 2026-09281 — Submission for OMB Review; Comment Request
The Department of Agriculture is asking for public feedback on a plan to improve markets for American farmers by making it easier to sell their products directly and build stronger local food networks. This update aims to boost farming communities and streamline how information is collected, with comments due by June 10, 2026. Farmers, co-ops, and anyone involved in agriculture will feel the positive changes, with no new costs announced yet.
Next: 2026-09284 — Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Generic Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate
The FDA is gearing up to renew the Animal Generic Drug User Fee Act (AGDUFA) before it expires in September 2028. They’re inviting vets, scientists, and animal drug makers to join regular meetings starting June 2026 to help shape the next phase. This means ongoing teamwork and funding to keep affordable animal medicines coming!